is associated with a decreased use of narcotics and antiemetic medicaments, and shorter hospital stay. We evaluated the efficacy of pain pump catheters on massive weight loss patients undergoing bodycontouring abdominoplasty.
METHODS:
Patients underwent primary abdominoplasty at a single center were retrospectively reviewed. Bodylift, lipoabdominoplasties, panniculectomies, secondary operations and pain management with patient controlled epidural analgesia were excluded. There were a total of 123 patients, whom 61 were eligible for this study. Patients were divided into two groups on basis of the pain pump use: pain pump group (24 patients) and the control group (37 patients). Patient demographics, perioperative parameters, postoperative complications, total morphine equivalents and hospital stay were compared. Primary outcome was the total amount of opioid use during the hospital stay. Secondary outcomes were the length of hospital stay and early postoperative complications (<30 days).
RESULTS:
The two groups were comparable on demographics, operative time and tissue resection weight. A significantly decreased use of opioids was observed after using pain pump versus control (14.0 ± 13.9 mg vs 74.6 ± 73.3 mg, p<0.001). Similarly, the length of hospital stay was significantly shorter among the pain pump group (3.1 ± 1.1 days vs 3.8 ± 1.0 days, p=0.023). No significant differences were detected in early postoperative complications. Although not statistically significant, a tendency to higher seroma rate was found among the pain pump group (25.0% vs 13.5%, p=0.315).
CONCLUSIONS:
On massive weight loss patients undergoing abdominoplasty, the use of local anaesthetic pain catheters is associated with a decreased use of opioids and might decrease the hospital stay. Further studies are needed to validate this treatment modality.
SKIN REJUVENATION THROUGH HIF-1Α UPREGULATION -A NEW TREATMENT PARADIGM IN ANTI-AGING MEDICINE

Dominik Duscher, GERMANY
INTRODUCTION: Skin changes are among the most visible signs of aging. With aging the skin thins and changes in the connective tissue reduce the skin's strength and elasticity. The blood vessels of the dermis become more fragile. This leads to bruising and impairments in the regenerative capacity of aging skin. The hypoxia-induced factor HIF-1α is a master transcription factor regulating tissue homeostasis by controlling the cellular response to stress, injury and ischemia. Studies show that aging leads to an increasing limitation of HIF-1α activity, which in turn causes chronic regeneration and wound healing disorders. Recent evidence suggests that upregulation of HIF-1α can regenerate aging skin on a molecular level. Here we present anti-aging effects linked to upregulation of HIF-1α expression through local removal of free iron in cutaneous tissue via the small molecule Deferiprone.
METHODS:
We characterized the effects of the iron chelator and HIF-1α activator Deferiprone on aged dermal cells in vitro via gene expression and protein analysis. Next a topical cutaneous application of Deferiprone was formulated and tested in 30 healthy volunteers in a dermatologically controlled, randomized, split face study over 6 weeks. Skin roughness, moisture, barrier function and elasticity were measured. Wrinkle severity was additionally rated by independent expert observers.
RESULTS:
Deferiprone significantly increased regenerative cytokine expression of dermal cells in vitro. In the clinical study a significant improvement of skin surface roughness, moisture and elasticity could be detected. Skin barrier function was unaffected. Expert assessment demonstrated significant wrinkle reduction.
CONCLUSION:
The application of the iron chelator and HIF-1α activator Deferiprone resulted in rejuvenation on both the cellular and the tissue level leading to significant improvements of skin quality and appearance without any signs of irritation.
